American healthcare company Eli Lilly said it has been alerted on the seizure of “suspicious and counterfeit products” that allegedly carry its product brand name Mounjaro (Tirzepatide).
Mounjaro is prescribed to treat obesity and has been in the headlines, as the scramble for GLP-1 drugs for weight-loss and diabetes get fuelled beyond the doctor’s chambers, through peer-pressure and online hard-sell, among others.
“The said seizure resulted from an enforcement drive conducted in Gurugram by officials from the state drugs regulatory authority, Haryana,” an Eli Lilly and Company (India) spokesperson told businessline.
The company was responding to reports that ₹70 lakh worth of fake Mounjaro had been seized in Gurugram.
“Lilly takes patient safety extremely seriously and welcomes the regulatory authority’s action against illicit medicines. We are actively supporting the investigation and will continue to work with regulatory and law enforcement authorities worldwide to protect patients from the risks of counterfeit products. Stronger, coordinated enforcement must be sustained if we are to protect patients from unsafe fake medicines,” the company said.